spacer
home > epc > autumn 2003 > e-business in pharmacovigilance
PUBLICATIONS
European Pharmaceutical Contractor

e-Business in Pharmacovigilance

The greatest challenge of the 21st Century will be the introduction of integrated e-business processes into the daily routine of pharmacovigilance for all aspects of information creation, analysis and communication. The electronic communication is, however, only the externally visible part of information handling. The better the processes that precede or follow the communication are integrated and supported by intelligent data handling or production techniques, the higher the benefit from e-business.

In pharmacovigilance the task of collection, documentation distribution and regulatory reporting of case reports on adverse experiences related to drugs by pharmaceutical companies and regulatory authorities is predominant. Though this activity is only the first step in a decision-making process to determine the risk profile and ultimately the risk benefit ratio of a drug, it devours vast resources and is in the focus of most regulatory compliance measures. Individual case safety reports (ICSR) are exchanged through a tight and highly regulated network of mutual obligations. The same case safety report will therefore appear in multiple institutions and will be entered into a database.

Every day thousands of case safety reports (adverse event reports) are distributed throughout the world. The FDA alone received 276,000 case reports in 1999. There is reason to believe that this transaction is probably the most frequent communication in the pharmaceutical world. Until now, case safety reporting relied largely on paper-based formats, such as the CIOMS, MedWatch, Yellow Card, BfArM and others.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Peter-Christoph Schulz, Safety Officer at Bayer Vital GmbH

Dr Peter-Christoph Schulz is the Safety Officer at Bayer Vital GmbH, the German marketing organisation for the pharmaceutical products of Bayer AG. His current responsibilities include case handling and regulatory issue management, as well as IT development.

Dr Schulz's special interests include systems analysis, process engineering and application development for cardiology (EKG, Holter Monitoring), hospitals and pharmacovigilance. After the completion of medical school and service as a Medical Officer in the army, Dr Schulz trained in internal medicine in institutions in Germany and the US.

spacer
Dr Peter-Christoph Schulz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Safe’n’Spray™, the smart electronic concept device with child-resistant and locking features, wins the ‘Best Innovation In Drug Delivery Device’ Award at Pharmapack 2020

On February 5th, during the Pharmapack Awards Ceremony, Safe’n’Spray, Nemera’s smart electronic concept device with child-resistant and locking features, was celebrated as the “Best Innovation in Drug Delivery Device”.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

 
Industry Events

Clinical Trial Supply Europe

11-12 March 2020, Madrid, Spain

The 21st annual edition promises to grow on the success of 2019’s excellent conference which saw delegates from Europe’s largest pharmaceutical companies and biotech innovators come together to discuss, debate and unpack the latest trends in clinical supply chain innovation. 2020 will offer delegates the opportunity to address the growing need for agility within the supply chain in response to increasingly complex trial demands. With a stream dedicated to supply operations and another to innovative uses of technology in the supply chain, delegates will get the chance to gain practical take-aways that they can apply to their own studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement